Ardelyx Inc
ARDX4.395USD
+0.065+1.50%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.05BValor de mercado
PerdaP/L TTM
Mais detalhes de Ardelyx Inc Empresa
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Informações da empresa
Código da empresaARDX
Nome da EmpresaArdelyx Inc
Data de listagemJun 19, 2014
CEOMr. Michael G. (Mike) Raab
Número de funcionários395
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 19
Endereço400 Fifth Avenue
CidadeWALTHAM
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02451
Telefone15107451700
Sitehttps://www.ardelyx.com/
Código da empresaARDX
Data de listagemJun 19, 2014
CEOMr. Michael G. (Mike) Raab
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
477.14K
-12.42%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
314.17K
-0.79%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
James Brady
James Brady
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Merdad Parsey, M.D., Ph.D.
Dr. Merdad Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Kelliher
Mr. Mike Kelliher
Chief Business Officer
Chief Business Officer
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
477.14K
-12.42%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
314.17K
-0.79%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
Por EmpresaUSD
Nome
Receita
Proporção
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
10.44%
The Vanguard Group, Inc.
6.70%
BlackRock Institutional Trust Company, N.A.
6.64%
Millennium Management LLC
5.06%
Macquarie Investment Management
4.66%
Other
66.50%
Investidores
Investidores
Proporção
Janus Henderson Investors
10.44%
The Vanguard Group, Inc.
6.70%
BlackRock Institutional Trust Company, N.A.
6.64%
Millennium Management LLC
5.06%
Macquarie Investment Management
4.66%
Other
66.50%
Tipos de investidores
Investidores
Proporção
Investment Advisor
27.48%
Investment Advisor/Hedge Fund
26.34%
Hedge Fund
13.49%
Research Firm
4.93%
Individual Investor
2.66%
Bank and Trust
0.37%
Pension Fund
0.36%
Family Office
0.09%
Insurance Company
0.03%
Other
24.24%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
460
181.09M
75.69%
+6.96M
2025Q1
470
173.66M
72.61%
+2.64M
2024Q4
452
158.29M
66.42%
-9.57M
2024Q3
441
149.04M
63.31%
-41.81M
2024Q2
420
152.02M
64.97%
-36.87M
2024Q1
399
149.36M
64.27%
-40.02M
2023Q4
363
143.31M
61.82%
-29.22M
2023Q3
347
131.10M
60.21%
-55.04M
2023Q2
355
129.77M
60.57%
-68.74M
2023Q1
359
119.15M
57.99%
-45.93M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
24.98M
10.44%
+589.07K
+2.42%
Mar 31, 2025
The Vanguard Group, Inc.
14.94M
6.25%
+634.58K
+4.44%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.88M
6.64%
-651.24K
-3.94%
Mar 31, 2025
Millennium Management LLC
12.10M
5.06%
+5.63M
+87.15%
Jun 17, 2025
Macquarie Investment Management
11.16M
4.66%
+811.55K
+7.84%
Mar 31, 2025
State Street Global Advisors (US)
10.18M
4.25%
-1.42M
-12.22%
Mar 31, 2025
Marshall Wace LLP
8.38M
3.5%
+8.27M
+7201.76%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.67M
2.37%
+162.88K
+2.96%
Mar 31, 2025
Nuveen LLC
3.39M
1.42%
+1.24M
+57.47%
Mar 31, 2025
Citadel Advisors LLC
3.19M
1.33%
+699.74K
+28.09%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Products ETF
2.03%
Harbor Human Capital Factor US Small Cap ETF
0.53%
Invesco NASDAQ Future Gen 200 ETF
0.48%
SPDR S&P Biotech ETF
0.36%
Direxion Daily S&P Biotech Bull 3X Shares
0.2%
First Trust Small Cap Growth AlphaDEX Fund
0.18%
Inspire Small/Mid Cap ESG ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Russell 2000 Growth ETF
0.06%
Ver Mais
Virtus LifeSci Biotech Products ETF
Proporção2.03%
Harbor Human Capital Factor US Small Cap ETF
Proporção0.53%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.48%
SPDR S&P Biotech ETF
Proporção0.36%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.2%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.18%
Inspire Small/Mid Cap ESG ETF
Proporção0.16%
Invesco Nasdaq Biotechnology ETF
Proporção0.1%
ProShares Ultra Nasdaq Biotechnology
Proporção0.1%
iShares Russell 2000 Growth ETF
Proporção0.06%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
